Coronavirus disease (COVID-19) is a global pandemic that is threatening the viability of healthcare systems worldwide. The virus responsible for the disease is also known as severe acute respiratory syndrome coronavirus 2 and abbreviated as SARS-CoV-2. The eruption started in China on December 29, 2019, and by March 2020, it had spread to at least 180 countries and territories worldwide. [Read more…]
Athersys’ MultiStem® Therapy for COVID-19 Designated “Highly Relevant” by BARDA
Headquartered in Cleveland, Ohio, Athersys is a biotech company focused on the development of novel cell therapeutics. With acute respiratory distress syndrome (ARDS) identified as a leading cause of death in COVID-19 patients, Athersys is working fast to launch a pivotal trial of its MultiStem® cell therapy product for the treatment of this life-threatening condition. [Read more…]
Pluristem Treated First Three COVID-19 Patients in Israel under Compassionate Use
-
Pluristem Therapeutics expects to treat more patients in Israel in the near future
-
It is in discussions with regulatory agencies in the U.S. and Europe to define its clinical strategy for COVID-19
Promising Drugs, Antibodies, and Vaccines in Development Against COVID-19
What are the most promising drugs, antibodies, and vaccines in development against COVID-19? Our team sifted through hundreds of articles and research papers to identify the most promising ones. In most cases, these drugs, vaccines and antibodies are already in use for other diseases, making it easier to leverage them in the fight against the Coronavirus. [Read more…]
AlloVir & Baylor College of Medicine to Develop Allogeneic T-Cell Therapies for COVID-19
AlloVir’s proprietary technology is designed to develop virus specific T-cell therapies with potential to treat and prevent several devastating viral diseases with each single cell therapy product.
CAMBRIDGE, Mass & HOUSTON- AlloVir, a late-clinical stage T-cell immunotherapy company, today announced the expansion of its research and development collaboration with Baylor College of Medicine to include the discovery and development of allogeneic, off-the-shelf, virus specific T-cell therapies to combat SARS-CoV-2, the virus that causes COVID-19. [Read more…]